In this interview, Dipak Panigrahy, MD discusses the emerging impact of specialized pro-resolving mediators (SPMs) on tumor size and growth, highlighting his work with several preclinical models including pancreatic cancer and breast cancer. Dr. Panigrahy outlines the reduction in metastases seen in preclinical cancer models, including pancreatic cancer, following treatments with various SPMs. Finally, Dr Panigrahy describes results in preclinical models showing that SPM treatment helps to clear tumor debris caused by standard of care cancer treatments.
Dipak Panigrahy, MD, is an Assistant Professor of Pathology at the Beth Israel Deaconess Medical Center at Harvard Medical School
From the 16th International Conference on Bioactive Lipids in Cancer, Inflammation and Related Diseases, October 2019 in St Petersburg, Florida
